Results 191 to 200 of about 185,707 (269)

Associations Between Changes in Pain Sensitization and Disease Activity Following Disease‐Modifying Antirheumatic Drug Therapy in Established Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Abnormalities in pain regulatory mechanisms are common in patients with rheumatoid arthritis (RA). We investigated whether pain sensitization changes after treatment with a disease‐modifying antirheumatic drug (DMARD) and explored associations between changes in pain sensitization and disease activity.
Burcu Aydemir   +10 more
wiley   +1 more source

Glucocorticoid therapy and adrenal suppression

open access: bronze, 2017
Damir Benc   +9 more
openalex   +2 more sources

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit   +13 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

open access: yesArthritis &Rheumatology, EarlyView.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie   +8 more
wiley   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

Home - About - Disclaimer - Privacy